Human Xt (HUMX) AI Stock Analysis

• Market Cap: 8.37M
• Dividend Yield: N/A
• Average Volume (3M): 16.97K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 21
• Sector: Technology
• Sector Strength: 87
• Industry: Medical - Devices
• EPS (TTM): -0.86
• Shares Outstanding: 26,756,048
• 10 Day Avg. Volume: 31,114
• 30 Day Avg. Volume: 16,967
• PEG Ratio: 0.03
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

Human Xt's stock performance is weighed down by significant financial difficulties, including declining revenues and persistent losses. The technical analysis is mixed, showing some potential for volatility but no clear trend. Valuation metrics are unattractive due to negative earnings. The company's dire financial health is the primary concern, overshadowing any technical or valuation considerations.

Human Xt Business Overview & Revenue Model

Company Description

Human Xtensions Ltd. develops, manufactures, markets and sells a modular medical device for minimally invasive surgical operations. It offers HandX, a handheld electromechanical device for use in laparoscopic procedures; Fenestrated Grasper; Monopolar Hook; and Needle Holder. The company was incorporated in 2012 and is based in Netanya, Israel.

How the Company Makes Money

Human Xt (HUMX) generates revenue through the sale of its smart wearable devices and augmented reality applications, which are available to both individual consumers and corporate clients. The company also offers AI-driven software solutions on a subscription basis, providing continuous updates and support. Key revenue streams include direct product sales, subscription fees for software services, and partnerships with technology firms to integrate HUMX's solutions into broader ecosystems. Additionally, strategic alliances with enterprise clients in various industries allow the company to create customized solutions that cater to specific business needs, thereby enhancing its earnings.

Human Xt Financial Statement Overview

Summary

Human Xt faces significant financial challenges with declining revenues, persistent losses, and diminishing equity. While the absence of debt in 2024 offers some relief, the negative margins and cash flow issues highlight the need for substantial operational restructuring to achieve financial stability and growth.

Income Statement

Human Xt has been experiencing declining revenue from 2020 to 2024, with a sharp decrease in 2024 to $665,000 from $4,950,000 in 2023. Gross profit margin turned negative in 2024, indicating cost inefficiencies or pricing pressures. Net profit margin remains deeply negative at -3455.64% for 2024, reflecting substantial losses. EBIT and EBITDA margins are also negative, demonstrating ongoing operational challenges.

Balance Sheet

The company's equity ratio decreased from 89.61% in 2020 to 44.34% in 2024, indicating reduced financial stability. Despite having no debt in 2024, the company has been eroding its equity base. Return on equity remains negative at -788.45% in 2024 due to continuous losses. The company's cash reserves have significantly decreased, impacting liquidity.

Cash Flow

Operating cash flow remains negative, though free cash flow improved slightly in 2024 due to reduced capital expenditure. The free cash flow to net income ratio, however, is unfavorable, as operating losses persist. The company's ability to generate cash from operations is a concern, though reduced investing and financing cash outflows provide some relief.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.52M	665.00K	4.95M	3.17M	2.79M	20.69M
Gross Profit	1.46M	-2.68M	2.56M	2.43M	1.62M	10.08M
EBITDA	-27.92M	-21.63M	-34.54M	-41.38M	-50.33M	-26.02M
Net Income	-29.31M	-22.97M	-36.63M	-44.59M	-53.62M	-28.54M
Balance Sheet
Total Assets	20.55M	6.57M	35.02M	72.33M	120.51M	166.34M
Cash, Cash Equivalents and Short-Term Investments	12.34M	4.03M	25.06M	59.65M	103.79M	148.31M
Total Debt	1.02M	0.00	1.69M	2.67M	6.07M	7.55M
Total Liabilities	7.64M	3.66M	8.92M	10.55M	15.97M	17.52M
Stockholders Equity	12.91M	2.91M	26.11M	61.78M	104.53M	148.82M
Cash Flow
Free Cash Flow	-27.30M	-20.85M	-34.50M	-42.17M	-42.63M	-27.50M
Operating Cash Flow	-27.29M	-20.84M	-34.31M	-41.73M	-42.19M	-27.26M
Investing Cash Flow	20.51M	13.19M	19.29M	15.16M	-44.28M	2.11M
Financing Cash Flow	-1.54M	-957.00K	-1.92M	-2.60M	-2.45M	150.03M

Human Xt Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:HUMX, the sentiment is Negative. The current price of 34.9 is above the 20-day moving average (MA) of 34.76, above the 50-day MA of 33.83, and above the 200-day MA of 33.81, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 37.62 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:HUMX.

Human Xt Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	£566.00M	24.41	-6.00%	2.49%	3.52%	-29.29%
HUMX	40 Underperform	8.37M	―		―	―	―
BIOV		26.78M	42.42		―	―	―
ALMD		31.04M	―		―	―	―
EMTC.M		20.86M	―		―	―	―
BCUR		22.29M	―		―	―	―
MPRS		7.18M	―		―	―	―